Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG)

Introduction The addition of bevacizumab to the first-line chemotherapy of advanced non-small cell lung cancer (NSCLC) of non-squamous histology has been shown to improve survival. A multicenter, single-arm, phase IV study was conducted in order to evaluate the efficacy and toxicity of frontline bev...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer chemotherapy and pharmacology 2016-08, Vol.78 (2), p.369-376
Hauptverfasser:	Matikas, A., Kentepozidis, Ν., Ardavanis, A., Vaslamatzis, M., Polyzos, A., Emmanouilides, Ch, Katsaounis, P., Koinis, F., Xynogalos, S., Christopoulou, A., Ziras, N., Tegos, Th, Prinarakis, E., Hatzidaki, D., Georgoulias, V., Kotsakis, A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Bevacizumab - administration & dosage Bevacizumab - adverse effects Cancer Research Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Disease-Free Survival Female Humans Lung Neoplasms - drug therapy Lung Neoplasms - pathology Male Medicine Medicine & Public Health Middle Aged Neoplasm Metastasis Neoplasm Recurrence, Local Oncology Original Article Patient Selection Pharmacology/Toxicology Survival Rate Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!